首页> 美国卫生研究院文献>Human Vaccines Immunotherapeutics >Strong HCV NS3/4a NS4b NS5a NS5b-specific cellular immune responses induced in Rhesus macaques by a novel HCV genotype 1a/1b consensus DNA vaccine
【2h】

Strong HCV NS3/4a NS4b NS5a NS5b-specific cellular immune responses induced in Rhesus macaques by a novel HCV genotype 1a/1b consensus DNA vaccine

机译:新型HCV基因型1a / 1b共有DNA疫苗在恒河猴中诱导的强HCV NS3 / 4aNS4bNS5aNS5b特异性细胞免疫应答

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Chronic HCV is a surreptitious disease currently affecting approximately 3% of the world's population that can lead to liver failure and cancer decades following initial infection. However, there are currently no vaccines available for the prevention of chronic HCV. From patients who acutely resolve HCV infection, it is apparent that a strong and broad cytotoxic T lymphocyte (CTL) response is important in HCV clearance. DNA vaccines are naked plasmid DNA molecules that encode pathogen antigens to induce a pathogen-specific immune response. They are inexpensive to produce and have an excellent safety profile in animals and humans. Additionally, DNA vaccines are able to induce strong CTL responses, making them well-suited for an HCV vaccine. We aimed to maximize vaccine recipients' opportunity to induce a broad T cell response with a novel antigenic sequence, multi-antigen vaccine strategy. We have generated DNA plasmids encoding consensus sequences of HCV genotypes 1a and 1b non-structural proteins NS3/4a, NS4b, NS5a, and NS5b. Rhesus macaques were used to study the immunogenicity of these constructs. Four animals were immunized 3 times, 6 weeks apart, at a dose of 1.0mg per antigen construct, as an intramuscular injection followed by in vivo electroporation, which greatly increases DNA uptake by local cells. Immune responses were measured 2 weeks post-immunization regimen (PIR) in immunized rhesus macaques and showed a broad response to multiple HCV nonstructural antigens, with up to 4680 spot-forming units per million peripheral blood mononuclear cells (PBMCs) as measured by Interferon-γ ELISpot. In addition, multiparametric flow cytometry detected HCV-specific CD4+ and CD8+ T cell responses by intracellular cytokine staining and detected HCV-specific CD107a+/GrzB+ CD8+ T cells indicating an antigen specific cytolytic response 2 weeks PIR compared with baseline measurements. At the final study time point, 6 weeks PIR, HCV-specific CD45RA- memory-like T cells remained detectable in peripheral blood. Data presented in this manuscript support the notion that vaccine immunogenicity studies using a macaque model can be used to depict key anti-HCV nonstructural antigenic cellular immune responses and support the development of DNA-based prophylactic HCV vaccines.
机译:慢性丙型肝炎是一种秘密疾病,目前影响全球约3%的人口,在最初感染后数十年内可能导致肝衰竭和癌症。但是,目前没有预防慢性HCV的疫苗。从能急性解决HCV感染的患者中,很明显,强烈而广泛的细胞毒性T淋巴细胞(CTL)反应对HCV清除很重要。 DNA疫苗是编码病原体抗原以诱导病原体特异性免疫反应的裸质粒DNA分子。它们的生产成本低廉,并且在动物和人类中具有出色的安全性。此外,DNA疫苗能够诱导强烈的CTL反应,使其非常适合HCV疫苗。我们旨在通过新的抗原序列,多抗原疫苗策略,最大限度地提高疫苗接种者诱导广泛T细胞反应的机会。我们已经产生了编码HCV基因型1a和1b非结构蛋白NS3 / 4a,NS4b,NS5a和NS5b共有序列的DNA质粒。猕猴被用来研究这些构建体的免疫原性。以肌内注射,体内电穿孔的方式,以每只抗原构建体1.0mg的剂量对4只动物进行3次免疫,间隔6周,进行免疫,这大大增加了局部细胞对DNA的吸收。免疫后2周,在免疫恒河猴中测量了免疫应答,并显示了对多种HCV非结构性抗原的广泛应答,按干扰素-法测定,每百万外周血单核细胞(PBMC)多达4680个斑点形成单位。 γELISpot。此外,多参数流式细胞术通过细胞内细胞因子染色检测到HCV特异性CD4 +和CD8 + T细胞应答,并检测到HCV特异性CD107a + / GrzB + CD8 + T细胞,与基线测量值相比,在2周PIR时表现出抗原特异性溶细胞应答。在最后的研究时间点,在外周血中仍可检测到6周的PIR,HCV特异性CD45RA记忆样T细胞。本手稿中的数据支持以下观点:使用猕猴模型进行的疫苗免疫原性研究可用于描述关键的抗HCV非结构性抗原性细胞免疫应答,并支持基于DNA的预防性HCV疫苗的开发。

著录项

相似文献

  • 外文文献
  • 中文文献
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号